Skye Bioscience to Share Insights at Health Care Conference
Skye Bioscience, Inc. (NASDAQ: SKYE), a dynamic clinical-stage biopharmaceutical company, is set to make a significant appearance at the upcoming TD Cowen 45th Annual Health Care Conference. With a clear focus on combating obesity and advancing metabolic health, CEO Punit Dhillon will deliver a thorough corporate overview and engage in one-on-one meetings with key stakeholders.
The Conference Details
The highly anticipated event is scheduled for March 5, 2025, where Skye will present from 11:10 AM to 11:40 AM ET. The conference not only presents an opportunity for Skye to highlight its groundbreaking research but also for industry professionals to learn more about its innovative approaches to treating metabolic disorders.
Webcast Access
For those unable to attend in person, a live and archived webcast of the presentation will be available through Skye's official website, allowing a broader audience to gain insights into the company's strategic direction and ongoing projects.
Innovative Therapeutics Development
Skye Bioscience is dedicated to unlocking new therapeutic paths for metabolic health by developing next-generation molecules that interact with G-protein coupled receptors. The firm leverages biologic targets with significant human proof of mechanism, aiming to produce therapeutics that not only break new ground but also stand out clinically and commercially.
Current Clinical Trials
In line with its mission, Skye is conducting an important Phase 2 clinical trial focused on nimacimab, which is a negative allosteric modulating antibody targeting the cannabinoid CB1 receptor and is expected to play a crucial role in obesity treatment. This trial also explores the effects of combining nimacimab with a GLP-1 receptor agonist, which could lead to synergistic effects in managing metabolic health.
Connecting with Stakeholders
The opportunity for one-on-one meetings during the conference signifies Skye's commitment to fostering connections with investors and industry leaders. Through these interactions, Skye aims to share its vision and the progress of its clinical endeavors, gaining invaluable insights from attendees.
Future Prospects
As the metabolic health landscape evolves, Skye Bioscience is poised to make substantial contributions through its innovative research and clinical trials. Stakeholders and potential investors are encouraged to attend the conference or access the webcast to understand more about the promising future Skye envisions.
Contact Information
For further inquiries, investors are invited to reach out via email. The Investor Relations team can be contacted at ir@skyebioscience.com or by calling (858) 410-0266. Skye also encourages media-related inquiries through LifeSci Communications, contacting Michael Fitzhugh at mfitzhugh@lifescicomms.com or by phone at (628) 234-3889.
Frequently Asked Questions
What will Skye Bioscience present at the conference?
Skye will deliver a corporate overview and discuss its innovative research in metabolic health.
When is the TD Cowen Health Care Conference?
The conference is scheduled for March 5, 2025, from 11:10 AM to 11:40 AM ET.
How can I access the presentation if I can't attend?
A live and archived webcast will be available on Skye's official website for those who are unable to attend the event.
What is Nimacimab?
Nimacimab is a negative allosteric modulating antibody being studied in a Phase 2 clinical trial to treat obesity by inhibiting the CB1 receptor.
How do I get in touch with Skye Bioscience's Investor Relations?
You can contact Investor Relations at ir@skyebioscience.com or by calling (858) 410-0266.
